Key Points {#FPar1}
==========

Agomelatine did not increase the risk of hospitalisation due to acute liver injury (ALI) in the studied populations when compared to citalopram. Results were robust in multiple sensitivity analyses.In the populations studied, risk minimisation measures were in place and may have contributed to the lower risk found for agomelatine when compared with citalopram. Thus, compliance with relevant contra-indications, precautions of use, and biological liver testing before and during treatment are still required to prescribe agomelatine.Of the other antidepressants, sertraline, escitalopram, mirtazapine, venlafaxine, duloxetine, and amitriptyline had a lower risk of ALI hospitalisation when compared to citalopram.

Background {#Sec1}
==========

Agomelatine (Valdoxan, Thymanax) is a melatonin receptor agonist and serotonin 5-HT~2C~ antagonist indicated for major depressive episodes in adults \[[@CR1]\]. Hepatotoxic reactions are an identified risk of agomelatine included in the European risk management plan and the drug label, which recommend that aminotransferase levels are checked before treatment initiation and then after 3, 6, 12, and 24 weeks and following a dose increase \[[@CR2]\]. While other antidepressant drugs used in Europe do not have similar recommendations, hepatotoxic reactions do occur with some of them. The severity and frequency of those reactions vary among antidepressants. According to studies based only on case reports, they seem to be more common and severe with use of tricyclic antidepressants and monoamine oxidase inhibitors than with use of serotonin norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors (0.5--1%) \[[@CR3], [@CR4]\]. Acute liver injury (ALI) refers to the sudden appearance of liver test abnormalities and encompasses a spectrum of clinical diseases ranging from mild biochemical abnormalities to acute liver failure \[[@CR5]\]. When known causes of ALI have been ruled out and criteria for causality of a specific drug are met, the term drug-induced liver injury is used instead \[[@CR5], [@CR6]\]. Standardised definitions of ALI for use in epidemiological studies have been proposed \[[@CR5], [@CR7]\], and the incidence of ALI related to antidepressant use requiring hospitalisation has been estimated to be one to four cases per 100,000 patient-years \[[@CR3]\].

Antidepressant drugs are currently among the most widely used drugs in Western countries \[[@CR8], [@CR9]\], and often patients using them have risk factors for ALI, such as alcohol and drug abuse and dependence, and metabolic syndrome \[[@CR10]--[@CR12]\]. Other risk factors for ALI include older age, female sex, concurrent use of hepatotoxic medications, previous acute and chronic hepatic, biliary, and pancreatic conditions, malnutrition, HIV infection, and chronic inflammatory diseases \[[@CR13], [@CR14]\].

Two previous studies on the risk of ALI associated with the use of duloxetine have been conducted using Ingenix Research Data Mart and the Optum Research Database in the United States \[[@CR15], [@CR16]\], suggesting an increased risk of ALI with duloxetine when compared with venlafaxine \[[@CR15], [@CR16]\] and selective serotonin reuptake inhibitors \[[@CR15]\].

The primary goal of this post-authorisation safety study \[[@CR17]\], using a nested case--control analysis, was to evaluate the risk of hospitalisation for ALI associated with agomelatine and eight other antidepressant drugs as used in current medical practice compared with citalopram.

Methods {#Sec2}
=======

Study Design and Study Period {#Sec3}
-----------------------------

In brief, we conducted a large, multinational, retrospective longitudinal cohort and nested case--control study comparing new users of agomelatine (main exposure of interest) and new users of eight other study antidepressants with new users of citalopram (common reference group). Citalopram was selected as a comparator because it was the most commonly used antidepressant in three of the four countries and, according to literature reviews available at the time of writing the protocol, was among the antidepressants with the least potential for hepatotoxicity \[[@CR3], [@CR4]\]. The other antidepressants were selected because they were commonly used across all countries. The study period in each data source started after the launch of agomelatine in the respective country (in 2009 or 2010) and ended with the last year for which data were available in each data source (2013 or 2014). The full study protocol can be accessed at the European Union Electronic Register of Post-Authorisation Studies (EU PAS Register \# EUPAS10446) \[[@CR18]\].

Setting {#Sec4}
-------

This study was conducted in automated health databases in four countries: Spain (SIDIAP \[Information System for Research in Primary Care\] \[[@CR19]\] and EpiChron Cohort \[EpiChron Research Group on Chronic Diseases\] \[[@CR20]\]), Germany (GePaRD \[German Pharmacoepidemiological Research Database\]) \[[@CR21]--[@CR23]\] and Denmark \[[@CR24]--[@CR29]\] and Sweden \[[@CR29]--[@CR31]\] (using their national registers). Characteristics of the databases are described in Online Resource 1 (see the electronic supplementary material).

Study Population {#Sec5}
----------------

The study cohort included all individuals aged 18 years or older at the date of the first-recorded prescription fill of any of the study antidepressants during the study period(s) who (1) had not received a prescription fill for the same study antidepressant within the prior 12 months (new users) and (2) had at least 12 months of continuous enrolment in the data source before the first prescription fill defining cohort entry. Thus, one patient could contribute to several antidepressant cohorts if eligibility criteria were fulfilled. For women, an additional eligibility criterion was absence of pregnancy at the start date of antidepressant use. Patients with a history of liver disease or risk factors for liver disease (e.g. alcohol and drug abuse and dependence-related disorders), chronic biliary or pancreatic disease, malignancy, or other life-threatening conditions (e.g. cancer, HIV infection) were excluded from the study cohort (see Online Resource 2 in the electronic supplementary material for a detailed list of exclusion criteria).

Endpoints Ascertainment: Selection of Cases and Controls {#Sec6}
--------------------------------------------------------

The primary endpoint was ascertained in all data sources and defined as any patient with a specific hospital discharge diagnosis code of ALI from either the International Classification of Diseases, 9th Revision (ICD-9) or the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10).

The secondary endpoint was defined as validated cases of ALI (see below) identified with specific and nonspecific[1](#Fn1){ref-type="fn"} hospital discharge diagnosis codes and was evaluated only in Spain (EpiChron and SIDIAP) and Denmark.

The exploratory tertiary endpoint was assessed based on specific and nonspecific codes identified in both hospital and outpatient settings and was evaluated in all data sources regardless of whether validation was feasible. A sensitivity analysis restricted to validated cases was conducted in the three data sources in which validation was implemented. The list of specific and nonspecific codes is included in the electronic supplementary material (Online Resource 3). The list of codes was adapted to the country-specific ICD classification system used. The investigators in each country reviewed the codes list and made small adaptations when necessary. Additionally, local clinicians were consulted.

Potential cases of ALI identified with specific and nonspecific codes were confirmed by validation processes according to the definition criteria established by an international expert working group \[[@CR5]\]. The definition criteria are based on increases in the levels of alanine aminotransferase (ALT), alkaline phosphatase (ALP), and bilirubin over the upper limit of normality (ULN) with less than 1 year of persistence: (≥ 5 × ULN ALT) or (≥ 2 × ULN ALP) or (≥ 3 × ULN ALT and \> 2 × ULN bilirubin). This study was not designed to evaluate causality at the individual level to ascertain whether a specific case with phenotypical ALI had drug-induced liver injury or not. Rather, the study was designed to examine the potential causal role of agomelatine and other antidepressants when compared with citalopram in the development of ALI at the population level. Thus, no formal evaluations using the Roussel Uclaf Causality Assessment Method (RUCAM) \[[@CR32]\] were implemented at the individual case level. Potential cases were adjudicated by trained clinicians based on review of information abstracted from medical records. This information included timing and results of liver enzymes and information on presence or absence of excluding conditions \[[@CR33]\]. Thus, the clinical reviewers were adjudicating whether the individual potential cases met the study definition criteria of ALI and whether excluding conditions were present, not whether they met criteria for causality between antidepressant use and liver injury. Validity of the electronic algorithms based on diagnosis codes used in the secondary and tertiary endpoints was assessed by calculating the positive predictive value (PPV), defined as the probability that a patient classified as a potential case was a confirmed case of ALI based on the reviewed data (excluding nonevaluable cases from the denominator).

In Germany, a companion external validation study (ALIVAL) of the ICD discharge and outpatient diagnosis codes for ALI was conducted in a German hospital to estimate the PPV of algorithms used in the GePaRD data source to identify potential cases of the primary and tertiary endpoints. In Sweden, no validation of cases was implemented.

In the case--control analysis, all ALI cases identified according to the definition of each endpoint in the study cohort were included as cases. Controls were selected from the study cohort using density sampling. Up to 20 controls per case were randomly selected from the risk set of each case. Controls were matched to cases on age and sex, index date, and calendar year of study (cohort) entry.

Exposure Variables and Confounding Factors {#Sec7}
------------------------------------------

Time at risk was defined according to the days of supply of each prescription fill plus a period of 40 days. Days of supply were the assumed number of days of treatment associated with each prescription fill. The period of 40 days was added to account for stockpiling and less than perfect adherence \[[@CR34]\].

In the nested case--control main analysis, use status was classified for each patient and each antidepressant into four mutually exclusive categories according to time at risk of the most recent prescription fill received on or before the index date:Current use: when the time at risk of the most recent prescription fill overlapped the index dateRecent use: when the time at risk ended within 60 days before the index datePast use: when the time at risk ended more than 60 days before the index dateNonuse: when there was no prescription fill of the study drug under consideration before the index date

Confounding factors were those related to the risk of ALI \[[@CR13], [@CR14], [@CR35]\] and to exposure to agomelatine or another study antidepressant. Age, sex, and year of entrance in the cohort (through matching); acute alcohol intoxication; obesity; other components of metabolic syndrome (hypertension and dyslipidaemia); diabetes; inflammatory bowel disease; pre-existing comorbidity measured by the Charlson Comorbidity Index; acute biliary and pancreatic disease; peptic ulcer disease; rheumatic diseases; concurrent use of hepatotoxic drugs (list of drugs available in Online Resource 4; see the electronic supplementary material); concurrent use of other antidepressants (different from study antidepressants); number of liver tests performed; and health care resource utilization measures were considered potential risk factors or confounders.

Statistical Analyses {#Sec8}
--------------------

Crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for ALI for current use of each study antidepressant were estimated using conditional logistic regression models, with current use of citalopram as the reference category (main analysis).

Crude ORs (and 95% CIs) were estimated including only the exposure variables in the conditional logistic regression model. Due to the matching of cases and controls and conditional analyses, these crude ORs were adjusted by age, sex, and calendar year at study entry, but were referred to as crude ORs regarding the rest of the confounders. Because of the low number of cases in some data sources, the original exposure variables had to be reclassified into fewer categories (i.e. current use vs. other), and in each of the separate logistical models comparing citalopram with each one of the other antidepressants, a new single exposure variable was created to classify current use status of the two antidepressants being compared.

Important risk factors and potential confounders were a priori included in the models. Other potential confounders were tested in a backward elimination process \[[@CR36]\] to avoid problems with zero cells in the analysis. In the nested case--control analysis, presence of risk factors and confounders was evaluated at any time before the index date, but some variables (e.g. concurrent use of hepatotoxic drugs) were evaluated just 6 months before the index date. In Online Resource 5, we include a table providing additional details on the timing of evaluation for the different potential confounders.

For each of the three study endpoints, meta-analysis was used to combine the adjusted OR estimates obtained from the nested case--control analysis in the different data sources. Combined ORs and 95% CIs for ALI were produced first using random-effects models \[[@CR37]\]. To assess heterogeneity in the meta-analysis, the *I*^2^ statistic was employed. When results were homogeneous across databases, fixed-effects models were used, and these results were presented in the results tables. When the *I*^2^ test statistic was 30% or higher for any of the antidepressants, random-effects models were presented for all antidepressants. Forest plots were created for each analysis table to display the adjusted combined and data source--specific results. When no events were observed in some of the data sources, we included only the results from data sources with observed events.

To check the robustness of the results, several planned sensitivity analyses were performed: the effect of adding 15 days or 60 days (instead of 40 days) to the days of supply of the most recent prescription before the index date was explored; the effect of recent and past use of each study antidepressant was compared with current use of citalopram; switching and multiple current use were compared with current single use of citalopram; and analyses restricted to cases without known causes of ALI were conducted. The implementation of those sensitivity analyses was limited in most data sources by the limited number of cases. In addition, two post hoc sensitivity analyses recommended by regulatory reviewers were implemented for the primary endpoint. In one, no exclusion criteria were implemented, and in the other, all study exclusion criteria were applied except those related to alcohol use disorder and drug abuse.

Results {#Sec9}
=======

A total of 3,238,495 new users of antidepressants (EpiChron, *n* = 185,628; SIDIAP, *n* = 203,101; the GePaRD, *n* = 817,072; the Danish National Health Registers, *n* = 664,205; and the Swedish National Registers in Sweden, *n* = 1,368,489) were included in the main analysis, of which 74,440 were new users of agomelatine (Table [1](#Tab1){ref-type="table"}). Agomelatine, the most recently launched of the studied antidepressants, was the least dispensed antidepressant in the study. A table presenting the distribution of the main confounder factors at cohort entry in each data source is included in Online Resource 6 (see the electronic supplementary material).Table 1Summary of the cohort attrition for users of study antidepressantsEpiChronSIDIAPGePaRDDenmarkSwedenAllAll users^a^New users included^b^All users^a^New users included^b^All users^a^New users included^b^All users^a^New users included^b^All users^a^New users included^b^All users^a^New users included^b^Citalopram19,2999016 (46.7%)69,53341,295 (59.4%)628,785229,895 (36.6%)356,097199,887 (56.1%)1,047,829302,719 (28.9%)2,121,543782,812 (36.9%)Agomelatine10,7008826 (82.5%)46863243 (69.2%)70,17930,155 (43.0%)22,13118,032 (81.5%)25,00314,184 (56.7%)132,69974,440 (56.1%)Fluoxetine27,40615,379 (56.1%)36,30619,235 (53.0%)110,54938,162 (34.5%)31,60115,475 (49.0%)203,92462,318 (30.6%)409,786150,569 (36.7%)Paroxetine43,80023,570 (53.8%)58,32631,392 (53.8%)82,16527,599 (33.6%)32,31115,581 (48.2%)111,95027,453 (24.5%)328,552125,595 (38.2%)Sertraline22,17711,054 (49.8%)37,38221,148 (56.6%)127,19543,461 (34.2%)167,973113,861 (67.8%)835,412290,107 (34.7%)1,190,139479,631 (40.3%)Escitalopram74,59146,129 (61.8%)42,91123,107 (53.8%)107,08139,287 (36.7%)99,19044,817 (45.2%)346,375107,027 (30.9%)670,148260,367 (38.9%)Mirtazapine34,87619,402 (55.6%)25,87414,161 (54.7%)473,284160,771 (34.0%)205,378124,647 (60.7%)674,519237,907 (35.3%)1,413,931556,888 (39.4%)Venlafaxine22,74810,577 (46.5%)24,96011,840 (47.4%)209,43874,850 (35.7%)116,79871,649 (61.3%)399,754102,116 (25.5%)773,698271,032 (35.0%)Duloxetine32,31420,899 (64.7%)19,28110,368 (53.8%)105,94732,357 (30.5%)49,50430,212 (61.0%)223,43564,850 (29.0%)430,481158,686 (36.9%)Amitriptyline31,79720,776 (65.3%)42,56227,312 (64.2%)412,180140,535 (34.1%)46,26130,044 (64.9%)354,381159,808 (45.1%)887,181378,475 (42.7%)Total319,708185,628 (58.1%)361,821203,101 (56.1%)2,326,803817,072 (35.1%)1,127,244664,205 (58.9%)4,222,5821,368,489 (32.4%)8,358,1583,238,495 (38.7%)*GePaRD* German Pharmacoepidemiological Research Database, *SIDIAP* Information System for Research in Primary Care^a^Total number of users before applying eligibility and exclusion criteria^b^Total number of users after applying eligibility and exclusion criteria. Percentages in this column are row percentages of the total number of all users

In the main analysis, a total of 472 cases were identified for the ALI primary endpoint (specific hospital discharge codes), ranging from 19 (SIDIAP) to 170 (Danish National Health Registers). Online Resource 7 presents the number of cases and controls in each data source and the association between potential confounders and the ALI primary endpoint in the multivariable adjusted models, which was different in the five data sources. Table [2](#Tab2){ref-type="table"} displays the number of new users in each antidepressant cohort and the number of cases and controls by endpoint, antidepressant cohort, and overall numbers.Table 2Number of new users in each antidepressant cohort and number of cases and controls by study endpoint and antidepressant cohortNew users, *N* (%)^a^\
\[*n* = 3,238,495\]Primary endpoint (specific hospital discharge codes)Secondary endpoint (specific and non-specific hospital discharge codes---only validated cases included)Tertiary endpoint (specific and non-specific hospital discharge and outpatient codes)Number of cases^b^ (%)\
\[*n* = 472\]Number of controls^c^ (%)\
\[*n* = 9438\]Number of cases^b^ (%)\
\[*n* = 178\]Number of controls^c^ (%)\
\[*n* = 3540\]Number of cases^b^ (%)\
\[*n* = 17,118\]Number of controls^c^ (%)\
\[*n* = 342,070\]Citalopram782,812 (24.2%)111 (23.5%)1790 (19.0%)45 (25.3%)806 (22.8%)2667 (15.6%)53,296 (15.6%)Agomelatine74,440 (2.3%)2 (0.4%)112 (1.2%)*n* \< 559 (1.7%)284 (1.7%)4771 (1.4%)Fluoxetine150,569 (4.6%)9 (1.9%)217 (2.3%)*n* \< 551 (1.4%)547 (3.2%)10,974 (3.2%)Paroxetine125,595 (3.9%)7 (1.5%)201 (2.1%)1 (0.6%)72 (2.0%)590 (3.4%)10,853 (3.2%)Sertraline479,631 (14.8%)41 (8.7%)805 (8.5%)13 (7.3%)314 (8.9%)775 (4.5%)15,412 (4.5%)Escitalopram260,367 (8.0%)25 (5.3%)490 (5.2%)16 (9.0%)255 (7.2%)603 (3.5%)12,902 (3.8%)Mirtazapine556,888 (17.2%)41 (8.7%)967 (10.2%)18 (10.1%)458 (12.9%)1348 (7.9%)23,433 (6.9%)Venlafaxine271,032 (8.4%)35 (7.4%)637 (6.7%)7 (3.9%)254 (7.2%)1178 (6.9%)19,900 (5.8%)Duloxetine158,686 (4.9%)11 (2.3%)322 (3.4%)2 (1.1%)122 (3.4%)502 (2.9%)9297 (2.7%)Amitriptyline378,475 (11.7%)22 (4.7%)467 (4.9%)3 (1.7%)125 (3.5%)1084 (6.3%)17,644 (5.2%)Percentages in each cell were obtained from the total number of ALI cases or controls included in the column headerDue to data protection policies, the exact number of cases could not be provided when the number of cases was less than 5*ALI* acute liver injury^a^Percentages in this column are row percentages of the total number of all users^b^This number represents the total number of ALI cases. Cases in the body of the table are only those identified among current users^c^This number represents the total number of controls. Controls in the body of the table are only those with current use of the antidepressant

Primary Endpoint {#Sec10}
----------------

Online Resource 8 presents the age- and sex-standardised incidence rates of ALI for the primary endpoint by data source and studied antidepressant. The estimates were imprecise, ranged from 0 to 27 cases per 100,000 person-years, and were overall within the range of the ALI incidence rates described previously in the literature \[[@CR38]\]. The PPVs for the specific codes used to identify the primary endpoint ranged from 60.0% (SIDIAP) to 84.2% (EpiChron) in the study data sources, and the PPV was 62.7% in the external validation study in Germany (ALIVAL).

Results of the case--control analyses for the current use of agomelatine compared with current use of citalopram are presented in Table [3](#Tab3){ref-type="table"}.Table 3Results for the primary endpoint and current use (agomelatine vs. citalopram) in each data source and combined in the main analysis and the two post hoc sensitivity analyses^a^EpiChron\
OR (95% CI)SIDIAP\
OR (95% CI)GePaRD\
OR (95% CI)Danish National Health Registers\
OR (95% CI)Swedish National Registers\
OR (95% CI)Combined\
OR (95% CI)Primary endpoint (specific codes, hospitalised patients) Main analysis^b^0.82 (0.06--10.70)--0.55 (0.06--4.72)0.30 (0.04--2.32)--0.48 (0.13--1.71)Sensitivity post hoc analyses No exclusion criteria applied0.66 (0.06--7.16)0.61 (0.08--4.87)0.36 (0.10--1.39)0.32 (0.12--0.84)0.26 (0.01--8.17)0.37 (0.19--0.74) Exclusion criteria applied, except alcohol and drug abuse1.60 (0.12--21.33)1.43 (0.15--13.84)0.51 (0.08--3.03)0.30 (0.09--1.00)0.16 (0.01--3.85)0.47 (0.20--1.07)*CI* confidence interval, *GePaRD* German Pharmacoepidemiological Research Database, *OR* odds ratio, *SIDIAP* Information System for Research in Primary Care^a^Adjusted for confounding factors; the list of confounders differed by data source. The following confounders were included in most analyses: obesity, hyperlipidaemia and hypertriglyceridaemia, diabetes, hypertension, indication of treatment with antidepressants for major depression, indication of treatment with antidepressants for anxiety disorders, indication of treatment with antidepressants for other mental and behavioural disorders, Charlson Comorbidity Index, number of liver tests performed, concurrent use of hepatotoxic drugs, and concurrent use of other antidepressants^b"^--^"^ indicates that the model did not converge

Current use of agomelatine compared with current use of citalopram yielded ORs below 1.00 in all data sources with cases (no cases under current use of agomelatine were identified in SIDIAP and Sweden) with imprecise estimates. The combined (meta-analysis) adjusted OR for current use of agomelatine compared with citalopram was 0.48 (95% CI 0.13--1.71).

In the post hoc sensitivity analysis without exclusions (including 4,833,774 new users of antidepressants, of which 117,240 were new users of agomelatine), more cases were identified, and therefore, the OR estimates were more precise and in line with the main analysis. The combined adjusted OR for current use of agomelatine compared with citalopram was 0.37 (95% CI 0.19--0.74). The point estimates were homogeneous across all data sources for the sensitivity analysis without exclusions.

In the post hoc sensitivity analysis including patients with disorders related to alcohol and drug abuse (3,531,529 new users of antidepressants, of which 84,210 were new users of agomelatine), the combined adjusted OR for current use of agomelatine compared with citalopram was 0.47 (95% CI 0.20--1.07). The individual point estimates from the different data sources were less homogeneous: both EpiChron and SIDIAP, which had the smallest agomelatine cohorts, showed OR estimates above 1.00 with wide 95% CIs.

Figure [1](#Fig1){ref-type="fig"} presents the combined results for current use of each antidepressant in the main analysis and the two post hoc sensitivity analyses for the primary endpoint. For all antidepressants except fluoxetine and paroxetine, the combined point estimates were less than 1.00 in the main analysis. The 95% CIs were more imprecise in the main analysis than in the two post hoc sensitivity analyses, in which all antidepressants had ORs below 1.00 when compared with citalopram.Fig. 1Current use combined adjusted estimates for all antidepressants (primary endpoint main and two sensitivity post hoc analyses removing exclusion conditions). Odds ratio estimates were adjusted for confounding factors. The list of confounders differed by data source and type of analysis (main vs. sensitive analyses). The following confounders were included in most analyses: obesity, hyperlipidaemia and hypertriglyceridaemia, diabetes, hypertension, indication of treatment with antidepressants for major depression, indication of treatment with antidepressants for anxiety disorders, indication of treatment with antidepressants for other mental and behavioural disorders, Charlson Comorbidity Index, number of liver tests performed, concurrent use of hepatotoxic drugs, and concurrent use of other antidepressants. *CI* confidence interval, *GePaRD* German Pharmacoepidemiological Research Database, *SIDIAP* Information System for Research in Primary Care

Results of the planned sensitivity analyses (including the ones assessing different exposure definitions and analysis excluding known causes of ALI) for agomelatine and the other antidepressants were, in general, consistent with the main analysis and produced combined OR point estimates for agomelatine below 1.00 for current use (data not shown). Results for all antidepressants, combined and in each individual data source, and for the three endpoints are available in the electronic supplementary material (Online Resources 9--11).

Secondary Endpoint {#Sec11}
------------------

The secondary endpoint included only cases that had been confirmed after validation, which resulted in a lower number of events than for the primary endpoint. A total of 178 confirmed cases (150 in Denmark, 20 in EpiChron, eight in SIDIAP) and 3540 controls were identified. Confirmed cases during current use of agomelatine were identified in Denmark only; the adjusted OR estimate for current use was 0.40 (95% CI 0.05--3.11). For the other antidepressants when compared with citalopram, most combined OR point estimates were less than one, except that of fluoxetine. The estimates were imprecise (Online Resource 10).

Tertiary Endpoint {#Sec12}
-----------------

Overall, there were 17,118 cases of the tertiary study endpoint and 342,070 controls. The GePaRD had overall the largest number of cases (11,917), followed by SIDIAP (2826), Sweden (1099), Denmark (1088), and EpiChron (268). The PPV of the tertiary endpoint cases was low in all data sources, but especially in SIDIAP (7.7%). The highest PPVs (47.0%) were found in Denmark and the ALIVAL external study (Germany, 45.1%). In EpiChron, the PPV was 25.4%. In Sweden, no validation of cases was implemented.

For this tertiary endpoint, the combined estimate for agomelatine for current use was 0.79 (95% CI 0.50--1.25). The results were heterogeneous (*I*^*2*^ = 71%, indicating the presence of strong heterogeneity). The individual data source--adjusted ORs for current use of agomelatine were also below 1.00, except in the GePaRD, and ranged from 0.36 (95% CI 0.11--1.25) in Sweden to 0.95 (95% CI 0.33--2.75) in EpiChron. In the GePaRD, the adjusted OR was 1.24 (95% CI 1.07--1.42) and contrasted with the ORs observed in Denmark and Sweden, which were approximately 0.5 (Online Resource 12). In Denmark, the adjusted OR estimate for current use of agomelatine was 0.44 (95% CI 0.22--0.87). In the sensitivity analysis that included only confirmed cases (confirmed cases available only in Denmark; see Online Resources 13) of the tertiary endpoint, the OR was 0.75 (95% CI 0.17--3.22).

For the other antidepressants (Online Resource 11), all combined OR estimates were between 0.94 and 1.11. There was an indication of heterogeneity for mirtazapine, duloxetine, and amitriptyline (*I*^*2*^ \> 50%, indicating at least moderate heterogeneity). The combined OR 95% CIs of the tertiary endpoint were more precise than for the other two endpoints. In the sensitivity analysis that included only confirmed cases (Online Resource 13), all combined OR estimates were below one except for duloxetine (OR 1.03; 95% CI 0.60--1.79).

Discussion {#Sec13}
==========

Use of agomelatine was not associated with higher risk of ALI hospitalisation compared with use of citalopram in a large cohort comprising 3.2 million new users of antidepressants in five populations from four countries: Spain, Denmark, Sweden, and Germany. Although precision of the combined risk estimates was low for the primary endpoint, the results were similar and more precise in the unrestricted sensitivity analyses and consistent both with the other sensitivity analyses and with the results of the other two endpoints considered. In the combined analysis, no increase in risk was observed in populations including alcoholic patients or patients with other various risk factors. For the other antidepressants, most presented ORs below 1, except for fluoxetine and paroxetine. Further, as for agomelatine, similar results were obtained when using other outcome definitions, that is, the secondary and tertiary endpoints.

The estimates of risk associated with agomelatine use in this study are consistent with those from a recent cohort study funded by the French National Agency for Medicines and Health Products Safety and conducted using the French health insurance database. This study did not find an increased risk of severe liver injury associated with the use of agomelatine compared with use of selective serotonin reuptake inhibitors (adjusted hazard ratio 1.07; 95% CI 0.51--2.23) \[[@CR39]\].

In our study, analyses of most study antidepressants yielded ORs of ALI hospitalisation lower than 1.00 when compared with citalopram in the combined analyses for all endpoints. Since we had no pre-suspicion that citalopram would carry a particularly high risk of ALI, the consistency in the direction of this association across antidepressants was unexpected. However, the limitations discussed hereafter, particularly those related to the low number of cases, preclude drawing definite conclusions. Citalopram is, in many countries, one of the first-line treatment options and is considered one of the safest antidepressants and could be selectively prescribed to those cases at the highest risk of ALI, which could potentially result in confounding by indication, but other antidepressants in this study share a similar drug prescription pattern. Although citalopram has been considered safe when compared with other antidepressants in analyses of spontaneous reports of adverse drug reactions \[[@CR40], [@CR41]\] and in reviews of published clinical data \[[@CR3]\], two epidemiological studies found an increased risk of drug-induced liver injury associated with citalopram use \[[@CR42], [@CR43]\]. Of note, the French study \[[@CR39]\] did not find any relevant differences in risk between selective serotonin reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors, and other antidepressants (e.g. agomelatine).

As in any study in automated data, misclassification of exposure status, occurrence of incident events, and the covariates to be included in the multivariable models is possible. In this study, this would likely have resulted in nondifferential misclassification of the endpoints, potentially biasing the estimates towards unity. However, small differences in misclassification of the exposure or the disease may result in bias towards or away from unity in an unpredictable manner \[[@CR44]\].

To minimise misclassification of endpoints, specific codes were used for the primary endpoint, and validation of the secondary endpoint that included nonspecific codes was implemented. Validation of potential cases was implemented in a sensitivity analysis of the tertiary endpoint. The sources and the quantity of information available differed across data sources and the underlying health care systems (e.g. body mass index was available in data sources with access to primary care data), which may explain some of the differences observed in the prevalence of some clinical features, as well as the differences observed across the study data sources in the PPVs and some OR estimates. For the primary endpoint, the PPVs of the specific codes ranged from 60% in SIDIAP to 84% in EpiChron and were consistent or higher than the estimates from previous studies \[[@CR45]--[@CR52]\]. In SIDIAP, access to hospital medical records was not available, and PPVs would have probably been higher otherwise. Some PPV estimates were imprecise, especially in SIDIAP and in the ALIVAL study, and differences between data sources could be also explained by random error. Importantly, however, the results of the secondary endpoint that included only confirmed cases were consistent with the results of the primary endpoint.

As already mentioned, the number of identified events of the primary and secondary endpoint was limited among agomelatine users and users of other antidepressants. For the tertiary endpoint, the number of cases was much higher (especially in the GePaRD and SIDIAP), yet the low PPVs observed for this endpoint definition limit the interpretation of these results in the analysis that included unconfirmed cases.

Patients taking agomelatine undergo routine liver enzyme monitoring as a risk minimisation measure. Therefore, patients at known risk of developing ALI may not have been prescribed agents (such as agomelatine) that are thought to be associated with an increased risk of ALI. Moreover, detection of liver enzyme elevations may be more likely in this group and prevent patients from starting treatment with agomelatine, or if agomelatine treatment has been started, treatment may be stopped earlier or cases of liver injury may be detected more frequently and earlier than if liver enzyme monitoring had not been conducted. In the context of observational studies using data from routine clinical practice, these scenarios could lead to selective prescribing, surveillance bias, or both. Selective prescribing, i.e. the less frequent prescription of agomelatine to patients with known risk factors for ALI or with evidence of existing liver damage measured by liver function tests, would shift the results in favour of agomelatine and lead to an apparently lower risk of ALI among agomelatine new users when compared with new users of citalopram. The comparison of the different antidepressant cohorts in the main analysis and in the sensitivity analysis including patients with known risk factors (data not shown) do not seem to indicate that agomelatine is less prescribed among patients with known risk factors (e.g. chronic liver conditions). Moreover, the results of the sensitivity analysis are consistent with the results of the main analysis, the latter excluding patients at risk of ALI, and show an OR estimate also below one and with larger precision. However, because of the risk minimisation measures in place, selective prescribing could still take place (e.g. agomelatine would not be prescribed to those patients with abnormal liver tests or those with contraindications and precautions of use according to approved label), and this cannot be assessed with the data available. Thus, it is plausible that selective prescribing may have influenced the results of the study, which need to be interpreted in the context of the risk minimisation measures in place for agomelatine. In fact, our results suggest that the risk minimization measures in place for agomelatine are effective.

Similarly, surveillance bias is unlikely to have had a large impact on the reported estimates for the primary and secondary endpoints, as these included only hospitalised and thereby more severe cases. In the combined results, no risk increase was found for the tertiary endpoint, which was in principle more sensitive to surveillance bias and misclassification than the primary and secondary endpoints. Surveillance bias would have resulted in ORs above 1.00. However, in the context of low PPVs, nondifferential misclassification would produce bias towards seeing no association.

The possibility of residual confounding cannot be discarded. As mentioned, the amount of information on some potential confounders (e.g. obesity) was limited in some of the data sources. Moreover, the limited number of identified ALI cases for the primary and secondary endpoints impacted the multivariable logistic regression strategy. To ensure a sufficient case-to-covariate ratio, the number of covariates and number of categories for categorical covariates included in the models had to be minimised. This resulted in more statistically stable models, but it may have increased the risk of residual confounding. Nevertheless, the restrictive cohort inclusion criteria implemented likely excluded most of the key potential confounders associated with ALI. Moreover, the post hoc analysis that did not impose any exclusion criteria resulted in a much larger number of new users of agomelatine (117,240) and of other antidepressants (4.8 million overall) and yielded more precise OR estimates for the primary endpoint that were consistent with those obtained in the main analysis. Also, control of confounding via multivariable models in those analyses did not have the limitations encountered in the main analysis of the primary endpoint.

The study had important strengths, first of which is that it evaluated more than 3 million (almost 5 million in one of the sensitivity analyses) new users of antidepressants and is the first study of this size to include also a validation component of the cases identified. Second, inclusion of multiple independent data sources and populations from different countries allowed evaluation of the consistency of the findings across five different, heterogeneous, automated, health care data sources. Finally, including three different endpoints with various degrees of PPV and yielding a varying number of cases created different perspectives for interpreting the study results.

Conclusion {#Sec14}
==========

The results of this study do not suggest that risk of hospitalised ALI with use of agomelatine (compared with use of citalopram) constitutes a public health problem, at least among patient populations in health care systems with prescription patterns and risk minimisation measures similar to those in this study. Thus, it is important to keep in place and comply with the existing risk minimisation measures for agomelatine, which our results suggest are effective in preventing ALI among users of agomelatine. When compared with citalopram, most antidepressants had OR point estimates less than 1.00 for hospitalised ALI. However, uncontrolled sources of bias could explain the results, and specific studies to investigate this potential association of citalopram with ALI are needed.
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The terms "specific" and "nonspecific" are used here to indicate groups of codes that have in previous studies showed more (specific) or less (nonspecific) positive predictive values for ALI.
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